The ALS-associated SPTLC1 variants cannot sense ceramide levels properly, thus leading to unregulated SPT activity and unrestrained sphingolipid biosynthesis (Fig. 7, upper right). This evidence concerns the gene AGXT and amyotrophic lateral sclerosis.